These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Price type key:
Federal Supply Schedule (FSS): generally available to all Federal Govt agencies /
'BIG4' prices: VA, DoD, Public Health & Coast Guard only /
National Contracts (NC): Available to specific agencies
Market Analysis and Price Projections for NDC 00173-0774
Last updated: February 13, 2026
Overview of NDC 00173-0774
NDC 00173-0774 corresponds to Pirtobrutinib (formerly known as LJH-958), a Bruton’s tyrosine kinase (BTK) inhibitor developed by Loxo Oncology, a subsidiary of Eli Lilly. It is designed for hematologic cancers, primarily relapsed or refractory B-cell malignancies, including mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL).
Market Penetration: Ibrutinib holds approximately 70% of the BTK inhibitor market. Acalabrutinib and Zanubrutinib share the remainder, with emerging interest in Pirtobrutinib due to its selectivity and reduced adverse events.
Regulatory Status
Filing and Approval: Filed for accelerated approval with the FDA in 2022 for specific hematologic indications.
Pending Decisions: Awaiting final approval or commercialization, expected 2023–2024.
Market Size and Demand
Addressable Patient Population: Estimated at 50,000–60,000 U.S. patients with relapsed/refractory MCL and CLL.
Growth Rate: The hematologic malignancy market is growing approximately 8% annually, driven by increasing diagnosis rates and treatment advances.
Pricing Analysis
Current Market Prices of Competitors:
Drug
Approximate Annual Cost
Notes
Ibrutinib (Imbruvica)
$145,000–$160,000
Approved since 2013, standard treatment
Acalabrutinib (Calquence)
$135,000–$150,000
Slightly newer, marketed as more selective
Zanubrutinib (Brukinsa)
$130,000–$145,000
Approved in 2019, early adoption stage
Pricing Strategy for Pirtobrutinib:
Based on its differentiated profile (potentially fewer side effects and improved efficacy), Eli Lilly could position Pirtobrutinib at a price point comparable to or slightly below existing competitors to accelerate market share. A suggested initial price range: $125,000–$140,000 annually.
Cost Breakdown Considerations:
Research & Development: Estimated at $800 million to $1 billion, including late-stage trials.
Manufacturing Costs: Approx. 15–25% of wholesale price.
Market Access & Payer Negotiations: Key factors influencing net prices, with rebates and discounts common.
Market Entry Strategies
Early Access Programs: Substantial in reducing payers' risk.
Opportunities: First-in-class status for non-covalent BTK inhibition, improved safety profile, expansion into earlier-line use.
Key Takeaways
Initial pricing set between $125,000 and $140,000 annually aligns with existing BTK therapies.
Market entry depends on overcoming competition from established drugs with broader approvals.
Revenue growth hinges on market adoption, clinical positioning, and reimbursement strategies.
FAQs
What factors influence the pricing of Pirtobrutinib?
Competitive landscape, clinical benefits over existing therapies, manufacturing costs, payer negotiations, and regulatory status.
How does Pirtobrutinib compare to existing BTK inhibitors?
It offers a non-covalent mechanism, potentially reducing adverse effects associated with covalent inhibitors like ibrutinib.
What is the potential global market for Pirtobrutinib?
Several billion dollars across North America, Europe, and Asia Pacific, assuming successful market adoption and international approvals.
What challenges could impact Pirtobrutinib’s market share?
Delays in approval, safety concerns, pricing pressure, and competition from new or existing approved therapies.
When is Pirtobrutinib expected to achieve significant sales milestones?
Post-2024, with accelerated growth in 2025–2026, assuming smooth approval, reimbursement, and clinical adoption.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
